Publications

Peer-Reviewed Journals and Publications (since 2000)

  1. Habuchi T, Suzuki T, Sasaki R, Wang L, …, Kato T. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res. 2000 Jan 15; 60(2):305-8.
  2. Sasaki R, Habuchi T, Sato K, …, Wang L, …, Kato T. The clinical utility of measuring total PSA, PSA density, gamma-seminoprotein and gamma-seminoprotein/total PSA in prostate cancer prediction. Jpn J Clin Oncol. 2000 Aug;30(8):337-42.
  3. Wang L, Akao T, Satoh S, Satoh K, Habuchi T and Kato T. A case of ureteral carcinoma with intermittent hydronephrosis. Akita Journal of Medicine, 27: 31-36, 2000.
  4. Habuchi T, Takahashi T, Kakinuma H, Wang L, …, Kato T. Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer. Oncogene. 2001 Jan 25;20(4):531-7.
  5. Wang L, Habuchi T, Takahashi T, Kamoto T, Zuo T, Mitsumori K, Tsuchiya N, Sato K, Ogawa O, Kato T. No association between HER-2 gene polymorphism at codon 655 and a risk of bladder cancer. Int J Cancer. 2002 Feb 20;97(6):787-90.
  6. Wang L, Habuchi T, Takahashi T, …, Kato T. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis. 2002 Feb;23(2):257-64.
  7. Wang L, Habuchi T, Mitsumori K, Li Z, …, Kato T. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer. 2003 Jan 1;103(1):116-20.
  8.  Li Z, Habuchi T, Tsuchiya N, Mitsumori K, Wang L, Ohyama C, Sato K, Kamoto T, Ogawa O, Kato T. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10. Carcinogenesis. 2004 Feb;25(2):237-40.
  9. Wang L, Habuchi T, Tsuchiya N, …, Kato T. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res. 2003 Aug 1; 63(15):4407-11.
  10. Wang LZ, Sato K, Tsuchiya N, Yu JG, Ohyama C, Satoh S, Habuchi T, Ogawa O, Kato T. Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population. Cancer Lett. 2003 Dec 8; 202(1):53-9.
  11. Kumazawa T, Tsuchiya N, Wang L, Sato K, Kamoto T, Ogawa O, Nakamura A, Kato T, Habuchi T. Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer. Int J Cancer. 2004 May 20; 110(1):140-4.
  12. Ito M, Habuchi T, Watanabe J, Higashi S, Nishiyama H, Wang L, Tsuchiya N, Kamoto T, Ogawa O. Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer. Urology, 2004 Jul; 64(1):74-8.
  13. Ichimura Y, Habuchi T, Tsuchiya N, Wang L, Oyama C, Sato K, Nishiyama H, Ogawa O, Kato T. Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant. J Urol. 2004 Aug; 172(2):728-32.
  14. Terai Y, Habuchi T, Sato K, Kakinuma H, Wang L, …, Ogawa O and Kato T. Absence of association between E-cadherin gene polymophism at position -160 in promoter region and risk of urothelial cancer. Akita Journal of Medicine, 30: 111-117, 2004.
  15. Satoh S, Horikawa Y, Kakinuma H, Tsuchiya N, Wang L, Kato T, Habuchi T. Clinical characteristics of normotensive renal transplant recipients with microalbuminuria and effects of angiotensin II type I receptor antagonist on urinary albumin excretion. Int J Urol. 2004 Aug;11(8):585-91.
  16. Narita S, Tsuchiya N, Wang L, Matsuura S, Ohyama C, Satoh S, Sato K, Ogawa O, Habuchi T, Kato T. Association of lipoprotein lipase gene polymorphism with risk of prostate cancer in a Japanese population. Int J Cancer. 2004 Dec 10; 112(5):872-6.
  17. Kakinuma H, Tsuchiya N, Habuchi T, Ohyama C, Matsuura S, Wang L, Nakamura A, Kato T. Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk. Prostate Cancer Prostatic Dis. 2004; 7(4):333-7.
  18. Tsuchiya N*, Wang L*, Horikawa Y, …, Habuchi T. CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia. Int J Oncol. 2005 Jan; 26(1):225-31. (* first co-author)
  19. Wang L, Mitoma J, Tsuchiya N,…, Fukuda M. An A/G polymorphism of core 2 branching enzyme gene is associated with prostate cancer. Biochem Biophys Res Commun. 2005 Jun 17; 331(4):958-63.
  20. Tsuchiya N, Wang L, Suzuki H, …, Habuchi T. Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol. 2006 May 1;24(13):1982-9.
  21. Bai XF, Liu JQ, Joshi PS, Wang L, Yin L, Labanowska J, Heerema N, Zheng P, Liu Y. Different Lineages of P1A-Expressing Cancer Cells Use Divergent Modes of Immune Evasion for T-Cell Adoptive Therapy. Cancer Res. 2006 Aug 15;66(16):8241-9.
  22. Wang L, Lin S,  Rammohan KW,  …,  Zheng P, Liu Y. A Di-nucleotide Deletion in CD24 Confers Protection against Autoimmune Diseases. PLoS Genetics, 2007 Apr 6;3(4):508-17.
  23. Zuo T, Wang L, Morrison C, …, Zheng P, Liu Y. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell, 2007 June 29; 129 (7): 1275-86.
  24. Zuo T, Liu RH, Zhang H, Chang X, Liu Y, Wang L, Zheng P and Liu Y.  FOXP3 is a novel transcription repressor for the breast cancer oncogene SKP2. J Clin Invest., 2007 Dec;117(12):3765-73.
  25. Chen GY, Chen C, Wang L, Chang X, Zheng P, and Liu Y. Broad Expression of the FoxP3 Locus in Epithelial Cells: a Caution against an Early Interpretation of Fatal Inflammatory Diseases Following In vivo Depletion of FoxP3-Expressing Cells. J Immunol, 2008 Apr 15;180(8):5163-6.
  26. Liu R, Wang L, Chen C, …, Liu Y, Zheng P. Laforin negatively regulates cell cycle progression through GSK-3{beta} dependent mechanisms. Mol Cell Biol. 2008 Dec; 28 (23):7236-44.
  27. Liu R*, Wang L*, Chen C, Katoh H, Chen C, Zheng P, Liu Y. FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/4 association to the locus. Cancer Res. 2009 Mar 15; 69 (6):2252-9. (* first co-author)
  28. Li D, Zheng L, Jin L, …, Wang L, …, Wang S. CD24 polymorphisms affect risk and progression of chronic hepatitis B virus infection. Hepatology. 2009 Sep;50(3):735-42.
  29. Wang L, Liu R, Li W, ..., Liu Y, Zheng P. Somatic Single-hits Inactivate the X-linked Tumor Suppressor FOXP3 in the Prostate. Cancer Cell. 2009 Oct 6;16(4):336-46.
  30. Zhou P, Fang X, McNally BA, …, Wang L, Liu Y, Zheng P. Targeting lymphotoxin-mediated negative selection to prevent prostate cancer in mice with genetic predisposition. Proc Natl Acad Sci U S A. 2009 Oct 6;106(40):17134-9.
  31. Liu Y, Wang L, Zheng P. X-linked Tumor Suppressors:  Perplexing Inheritance a unique Opportunity. Trends in Genetics, 2010 Jun;26(6):260-5.
  32. Yang WH, Gutierrez NM, Wang L, Ellsworth BS, Wang CM. Synergistic activation of the Mc2r promoter by FOXL2 and NR5A1 in mice. Biol Reprod. 2010 Nov;83(5):842-51.
  33. Zheng L, Li D, Wang F, …, Wang L, Liu Y, Wang S. Association between hepatitis B viral burden in chronic infection and a functional single nucleotide polymorphism of the PDCD1 gene. J Clin Immunol. 2010 Nov;30(6):855-60.
  34. Wang L*, Liu R, Ribick M, Zheng P, Liu Y. FOXP3 as an X-linked tumor suppressor. Discov Med. 2010 Oct; 10 (53): 322-8. (* corresponding author)
  35. Li W, Wang L, Katoh H, Liu R, Zheng P, Liu Y. Identification of a tumor suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate cancers. Cancer Res. 2011 Mar 15; 71 (6): 2162-71.
  36. Katoh H, Qin ZS, Liu R, Wang L, Li W, Li X, Wu L, Du Z, Lyons R, Liu CG, Liu X, Dou Y, Zheng P, Liu Y. FOXP3 Orchestrates H4K16 Acetylation and H3K4 Tri-Methylation for Gene Activation through Recruiting MOF and Displacing H3K4 Demethylase. Mol Cell. 2011 Dec 9; 44(5): 770-84.
  37. Liu R, Kain M, Wang L*. Inactivation of X-linked tumor suppressor genes in human cancer. Future Oncology. 2012 Apr; 8 (4): 463-81. (* corresponding author)
  38. Wang CM, Brennan VC, Gutierrez NM, Wang X, Wang L, Yang WH. SUMOylation of ATF3 alters its Transcriptional Activity on Regulation of TP53 Gene. J Cell Biochem. 2013 Mar;114(3):589-98.
  39. Wang L, Liu R, Li D, Lin S, Fang X, Backer G, Kain M, Rammoham K, Zheng P, Liu Y. A hypermorphic SP1-binding CD24 variant associates with risk and progression of multiple sclerosis. Am J Transl Res. 2012; Dec 1; 4(3): 347-56.
  40. Li W, Katoh H, Wang L, Yu X, Du Z, Yan X, Zheng P, Liu Y. FOXP3 Regulates Sensitivity of Cancer Cells to Irradiation by Transcriptional Repression of BRCA1. Cancer Res. 2013 Apr 1;73(7):2170-2180.
  41. Wang CM, Liu R, Wang L, Yang WH. Acidic residue Glu199 increases SUMOylation level of nuclear hormone receptor NR5A1. Int J Mol Sci. 2013 Nov 13;14(11):22331-45.
  42. Liu R, Li S, Yang WH, Wang L*. IPEX Syndrome, FOXP3 and Cancer. Journal of Syndromes. 2013; 1: 1-7. (* corresponding author)
  43. Wang CM, Liu R, Wang L, Nascimento L, Brennan VC, Yang WH. SUMOylation of FOXM1B Alters Its Transcriptional Activity on Regulation of MiR-200 Family and JNK1 in MCF7 Human Breast Cancer Cells. Int J Mol Sci. 2014;15(6):10233-51.
  44. Yi B, Yang J, Wang L*. The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line. Tumour Biol. 2014; 35(4):3229-35. (* corresponding author)
  45. Wang L*, Liu R, Chen GY, Zhou P, Li C, Ye P, Bassetti M, Zheng X, Wu W, Zhang Y, Zheng P, Liu Y.  Intracellular CD24 Disrupts ARF-NPM Interaction and Enables Mutational and Viral Oncogene-mediated p53 Inactivation. Nature Communication, 6, 20 January 2015 online Article number:5909doi:10.1038/ncomms 6909.  (* corresponding author)
  46. Liu R, Liu C, Chen D, Yang WH, Liu X, Liu CG, Dugas CM, Tang F, Zheng P, Liu Y and Wang L*. FOXP3 controls an miR-146/NFκB negative feedback loop that inhibits apoptosis in breast cancer cells. Cancer Research, in press. (* corresponding author)
  47. Liu R, Yi B, Wei S, Yang WH, Har KM, Chauhan P, Zhang W, Mao X, Liu X, Liu CG and Wang L*. FOXP3-microRNA-146-NF-κB axis and therapy for precancerous lesions in prostate.  Cancer Research, in press. (* corresponding author)

 

Lizhong Wang

Assistant Professor

 

  • :205-934-5948
  • DEPARTMENTDepartment of Genetics
    University of Alabama at Birmingham
  • COUNTRY USA